Genocea Biosciences Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genocea Biosciences stock.
View analyst ratings for Genocea Biosciences or view top-rated stocks.

Wall Street analysts have given Genocea Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genocea Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Genocea Biosciences.

Genocea Biosciences, Inc. (NASDAQ:GNCA) issued its quarterly earnings data on Wednesday, July, 28th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.02.
View Genocea Biosciences' earnings history.

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNCA shares have increased by 9.3% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued twelve-month target prices for Genocea Biosciences' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Genocea Biosciences' stock price to reach $6.67 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts' price targets for Genocea Biosciences or view top-rated stocks among Wall Street analysts.

5 employees have rated Genocea Biosciences CEO William Clark on Glassdoor.com. William Clark has an approval rating of 82% among Genocea Biosciences' employees.

Some companies that are related to Genocea Biosciences include Outlook Therapeutics (OTLK), Codiak BioSciences (CDAK), Autolus Therapeutics (AUTL), Lineage Cell Therapeutics (LCTX), CEL-SCI (CVM), Athira Pharma (ATHA), Oyster Point Pharma (OYST), Orchard Therapeutics (ORTX), Ikena Oncology (IKNA), Black Diamond Therapeutics (BDTX), Fusion Pharmaceuticals (FUSN), Gritstone bio (GRTS), SQZ Biotechnologies (SQZ), Gamida Cell (GMDA) and AVROBIO (AVRO).
View all of GNCA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GNCA stock can currently be purchased for approximately $2.00.

Genocea Biosciences has a market capitalization of $108.87 million and generates $1.36 million in revenue each year. The biotechnology company earns $-43,710,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

Genocea Biosciences employs 72 workers across the globe.

The official website for Genocea Biosciences is www.genocea.com.

Genocea Biosciences is headquartered at 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140.

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]